InnovAtlasMalaria No More
Pharmaceutical and biotech company

MalarVx, Inc.

Develop

MalarVx develops next-generation malaria vaccines using self-amplifying repRNA delivered with the LION™ nanocarrier platform and an in-vitro system for producing malaria sporozoites for whole-organism vaccine research and manufacturing.

0
Endemic countries
1
U.S. states
2
Products and programs
About

What they do

MalarVx develops next-generation malaria vaccines using self-amplifying repRNA delivered with the LION™ nanocarrier platform and an in-vitro system for producing malaria sporozoites for whole-organism vaccine research and manufacturing.1 Its headquarters, R&D, and manufacturing are based in Seattle, Washington.1 Its work is in the development stage, with its repRNA vaccine candidate in cGMP manufacturing and pre-IND development and its sporozoite-production platform being developed for scalable vaccine production.1

In the United States
  • Seattle, WA2,1Headquarters · Research and development · Manufacturing
Products and programs

In the field and in development

RepRNA/LION™ malaria vaccine program2,1
In-vitro sporozoite (IVS) production platform2,1
Where they work

Partnerships

No endemic-country partnerships are listed.

U.S. partners

Who they work with in the United States

Sources

Where this comes from

  1. 1Confirmed by the organization
  2. 2malarvx.com